Melatonin Attenuates Cyclophosphamide-Induced Primordial Follicle Loss by Interaction with MT
Reproductive sciences (Thousand Oaks, Calif.)
September 1, 2022
Ricássio S Barberino et al. (8 authors)
Journal ArticleResearch Support, Non-U.S. Gov'tAnimal Study
Extracted Claims (1)
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin | increase | ovarian function | mouse model | - | protective effect | #1 |
Abstract
This study evaluated the protective effect of melatonin before cyclophosphamide administration on ovarian function and its potential mechanism in a mouse model. Two studies were performed. In the first, mice were pretreated with melatonin (10, 20, or 30 mg/kg body weight, i.p.) once daily for 3 days, followed by injection with a single dose of cyclophosphamide (200 mg/kg body weight, i.p.) 30 min after the last melatonin injection. The second study analyzed whether melatonin type 1 and/or 2 receptors mediate the effects of melatonin on the ovary through administration of non-selective MT
Medical Subject Headings (MeSH)
AnimalsBody WeightCyclophosphamideFemaleMelatoninMiceOvaryProto-Oncogene Proteins c-akt
Study Links
PubMed ID34642909
Related Supplements